Xenon Pharmaceuticals Inc (FRA:XP0)
€ 37.4 0 (0%) Market Cap: 2.82 Bil Enterprise Value: 2.19 Bil PE Ratio: 0 PB Ratio: 3.45 GF Score: 50/100

Xenon Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 05:00PM GMT
Release Date Price: €39 (-1.02%)
Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Okay. Good morning. We'll continue with our next session. I'm Paul Choi, and I cover the small and mid-cap biotechnology sector here at the firm. And we'll continue with our next session, which is with Xenon. We're very pleased to have CEO, Ian Mortimer to my immediate left; and CFO, Sherry Aulin, to my far left.

What we'll do is some Q&A with the team. If along the way, anyone has questions in the audience or online, please raise your hand or shoot me an e-mail, and we'll read the questions anonymously over the path -- over the time. But maybe what we'll do, let's start with Ian, with -- maybe with some sort of high-level questions, which is for investors who may not be familiar or new to the Xenon story.

Questions & Answers

Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Can you maybe give us a quick overview of the company and then maybe a little bit on the sort of basic science that underpins your pipeline and developmental efforts with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot